Guideline Updates in Multiple Myeloma

News
Video

Joshua Richter, MD, FACP, presents recent National Comprehensive Cancer Network (NCCN) guideline updates in the treatment of multiple myeloma.

Related Videos
Muhamed Baljevic, MD
Sundar Jagannath, MBBS
Sundar Jagannath, MBBS
James Ignatz-Hoover, MD, PhD
Sundar Jagannath, MBBS
Elias Jabbour, MD
Joseph G. Jurcic, MD
Krina K. Patel, MD, MSc
Minoo Battiwalla, MD
Sundar Jagannath, MBBS
Related Content
FDA

OncLive’s April Roundup of Key FDA Decisions in Oncology

May 14th 2024
Article
Paul G. Richardson, MD

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

October 2nd 2023
Podcast
Kenneth C. Anderson, MD

The Benefits Outweigh the Risks: Unpacking the Recent ODAC Decisions in Myeloma

May 13th 2024
Article
Ajay K. Nooka, MD, MPH, FACP

FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma

September 21st 2023
Podcast
HR001 in NHL | Image Credit: © Dr_Microbe - stock.adobe.com

NXC-201 Receives Orphan Drug Designation in the European Union for Multiple Myeloma

May 3rd 2024
Article
Leland Metheny, MD, Case Western Reserve University

Homing in on Currently Recruiting Clinical Trials With Practice Changing Implications in Lymphoma and Myeloma

May 2nd 2024
Article